High remission rates for new CLL treatment
High remission rates for new CLL treatment
CLL from a patient and physician perspective
Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry
Results of a new phase Ib trial of voxtalisib in combination with chemoimmunotherapy
Highlights from the iwCLL conference: B-cell receptor Btk, PI3K and multi-molecular BCR inhibitors
A laboratory model of the hypoxic tumour microenvironment
Phase II study of idelalisib monotherapy in older CLL patients
History of the B-cell in its 50th anniversary year
Why doesn’t aspirin protect everyone from colorectal cancer?
ecancermedicalscience editor's choice for August 2015
Immune tolerance and the microenvironment in head and neck cancer
Genetics and epigenetics of lymphocyte development and transformation